Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized double-blind phase II/III study in the first-line treatment of advanced transitional cell carcinoma (TCC) of the urothelium comparing vinflunine/gemcitabine to placebo/gemcitabine in patients who are ineligible to receive cisplatin-based therapy

Next Previous
X
Search
Trial Profile

A multicenter, randomized double-blind phase II/III study in the first-line treatment of advanced transitional cell carcinoma (TCC) of the urothelium comparing vinflunine/gemcitabine to placebo/gemcitabine in patients who are ineligible to receive cisplatin-based therapy

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Vinflunine (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms VINCENT
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 30 Jun 2012 Planned number of patients changed from 450 to 500 as reported by European Clinical Trials Database record.
    • 25 Sep 2008 Status changed from active, no longer recruiting to completed.
    • 09 May 2008 The expected completion date for this trial has changed from 1 Oct 210 to 1 Sep 2008 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top